The role of iron in anthracycline cardiotoxicity

Frontiers in Pharmacology

Volumn 5 FEB, Issue , 2014, Pages

  Gammella, Elena ^a   Maccarinelli, Federica ^b   Buratti, Paolo ^a   Recalcati, Stefania ^a   Cairo, Gaetano ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Anthracyclines; Doxorubicin; Heart; Iron; Reactive oxygen species

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CD71 ANTIGEN; DOXORUBICIN; EPIRUBICIN; HFE PROTEIN; HYPOXIA INDUCIBLE FACTOR; IRON; IRON REGULATORY PROTEIN 1; IRON REGULATORY PROTEIN 2; METFORMIN; RAZOXANE; REACTIVE OXYGEN METABOLITE; TRANSFERRIN;

BONE MARROW TOXICITY; CARDIOMYOPATHY; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DRUG METABOLISM; DRUG STRUCTURE; HEART MITOCHONDRION; HEART PROTECTION; HUMAN; IRON BALANCE; IRON CHELATION; IRON METABOLISM; IRON OVERLOAD; IRON STORAGE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOGENESIS; SHORT SURVEY;

EID: 84895520569     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00025     Document Type: Short Survey

References (50)

1. Armenian, S. H., Ding, Y., Mills, G., Sun, C., Venkataraman, K., Wong, F. L., et al. (2013). Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation. Br. J. Haematol. 163, 205-213. doi: 10.1111/bjh.12516.
2. Arosio, P., and Levi, S. (2010). Cytosolic and mitochondrial ferritins in the regulation of cellular iron homeostasis and oxidative damage. Biochim. Biophys. Acta 1800, 783-792. doi: 10.1016/j.bbagen.2010.02.005.
3. Asensio-López, M. C., Sanchez-Mas, J., Pascual-Figal, D. A., De Torre, C., Valdes, M., and Lax, A. (2013a). Ferritin heavy chain as main mediator of preventive effect of metformin against mitochondrial damage induced by doxorubicin in cardiomyocytes. Free Radic. Biol. Med. 67C, 19-29. doi: 10.1016/j.freeradbiomed.2013.11.003.
4. Asensio-López, M. C., Sánchez-Más, J., Pascual-Figal, D. A., Abenza, S., Pérez-Martínez, M. T., Valdés, M., et al. (2013b). Involvement of ferritin heavy chain in the preventive effect of metformin against doxorubicin-induced cardiotoxicity. Free Radic. Biol. Med. 57, 188-200. doi: 10.1016/j.freeradbiomed.2012.09.009.
5. Bartnikas, T. B., Campagna, D. R., Antiochos, B., Mulhern, H., Pondarré, C., and Fleming, M. D. (2010). Characterization of mitochondrial ferritin-deficient mice. Am. J. Hematol. 85, 958-960. doi: 10.1002/ajh.21872.
6. Bernuzzi, F., Recalcati, S., Alberghini, A., and Cairo, G. (2009). Reactive oxygen species-independent apoptosis in doxorubicin-treated H9c2 cardiomyocytes: role for heme oxygenase-1 down-modulation. Chem. Biol. Interact. 177, 12-20. doi: 10.1016/j.cbi.2008.09.012.
7. Berthiaume, J. M., and Wallace, K. B. (2007). Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol. Toxicol. 23, 15-25. doi: 10.1007/s10565-006-0140-y.
8. Blanco, J. G., Leisenring, W. M., Gonzalez-Covarrubias, V. M., Kawashima, T. I., Davies, S. M., Relling, M. V., et al. (2008). Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 112, 2789-2795. doi: 10.1002/cncr.23534.
9. Cairo, G., and Pietrangelo, A. (2000). Iron regulatory proteins in pathobiology. Biochem. J. 352(Pt 2), 241-250. doi: 10.1042/0264-6021:3520241.
10. Cairo, G., and Recalcati, S. (2007). Iron-regulatory proteins: molecular biology and pathophysiological implications. Expert Rev. Mol. Med. 9, 1-13. doi: 10.1017/S1462399407000531.
11. Cairo, G., Recalcati, S., Pietrangelo, A., and Minotti, G. (2002). The iron regulatory proteins: targets and modulators of free radical reactions and oxidative damage. Free Radic. Biol. Med. 32, 1237-1243. doi: 10.1016/S0891-5849(02)00825-0.
12. Cairo, G., Tacchini, L., Pogliaghi, G., Anzon, E., Tomasi, A., and Bernelli-Zazzera, A. (1995). Induction of ferritin synthesis by oxidative stress. Transcriptional and post-transcriptional regulation by expansion of the "free" iron pool. J. Biol. Chem. 270, 700-703. doi: 10.1074/jbc.270.2.700.
13. Campanella, A., Rovelli, E., Santambrogio, P., Cozzi, A., Taroni, F., and Levi, S. (2009). Mitochondrial ferritin limits oxidative damage regulating mitochondrial iron availability: hypothesis for a protective role in Friedreich ataxia. Hum. Mol. Genet. 18, 1-11. doi: 10.1093/hmg/ddn308.
14. Canzoneri, J. C., and Oyelere, A. K. (2008). Interaction of anthracyclines with iron responsive element mRNAs. Nucleic Acids Res. 36, 6825-6834. doi: 10.1093/nar/gkn774.
15. Carvalho, F. S., Burgeiro, A., Garcia, R., Moreno, A. J., Carvalho, R. A., and Oliveira, P. J. (2014). Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Med. Res. Rev. 34, 106-135. doi: 10.1002/med.21280.
16. Cocco, E., Porrini, V., Derosas, M., Nardi, V., Biasiotto, G., Maccarinelli, F., et al. (2013). Protective effect of mitochondrial ferritin on cytosolic iron dysregulation induced by doxorubicin in HeLa cells. Mol. Biol. Rep. 40, 6757-6764. doi: 10.1007/s11033-013-2792-z.
17. Corna, G., Galy, B., Hentze, M. W., and Cairo, G. (2006). IRP1-independent alterations of cardiac iron metabolism in doxorubicin-treated mice. J. Mol. Med. (Berl.) 84, 551-560. doi: 10.1007/s00109-006-0068-y.
18. Corna, G., Santambrogio, P., Minotti, G., and Cairo, G. (2004). Doxorubicin paradoxically protects cardiomyocytes against iron-mediated toxicity: role of reactive oxygen species and ferritin. J. Biol. Chem. 279, 13738-13745. doi: 10.1074/jbc.M310106200.
19. Cusack, B. J., Gambliel, H., Musser, B., Hadjokas, N., Shadle, S. E., Charlier, H., et al. (2006). Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism. Cancer Chemother. Pharmacol. 58, 517-526. doi: 10.1007/s00280-006-0199-4.
20. Fogli, S., Nieri, P., and Breschi, M. C. (2004). The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J. 18, 664-675. doi: 10.1096/fj.03-0724rev.
21. Gianni, L., Herman, E. H., Lipshultz, S. E., Minotti, G., Sarvazyan, N., and Sawyer, D. B. (2008). Anthracycline cardiotoxicity: from bench to bedside. J. Clin. Oncol. 26, 3777-3784. doi: 10.1200/JCO.2007.14.9401.
22. Hentze, M. W., Muckenthaler, M. U., and Andrews, N. C. (2004). Balancing acts: molecular control of mammalian iron metabolism. Cell 117, 285-297. doi: 10.1016/S0092-8674(04)00343-5.
23. Hershko, C., Link, G., Tzahor, M., Kaltwasser, J. P., Athias, P., Grynberg, A., et al. (1993). Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine: studies in rat heart cells in culture. J. Lab. Clin. Med. 122, 245-251.
24. Ichikawa, Y., Ghanefar, M., Bayeva, M., Wu, R., Khechaduri, A., Naga Prasad, S. V., et al. (2014). Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J. Clin. Invest. 124, 617-630. doi: 10.1172/JCI72931.
25. Kwok, J. C., and Richardson, D. R. (2002). Unexpected anthracycline-mediated alterations in iron-regulatory protein-RNA-binding activity: the iron and copper complexes of anthracyclines decrease RNA-binding activity. Mol. Pharmacol. 62, 888-900. doi: 10.1124/mol.62.4.888.
26. Kwok, J. C., and Richardson, D. R. (2003). Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway. Mol. Pharmacol. 63, 849-861. doi: 10.1124/mol.63.4.849.
27. Kwok, J. C., and Richardson, D. R. (2004). Examination of the mechanism(s) involved in doxorubicin-mediated iron accumulation in ferritin: studies using metabolic inhibitors, protein synthesis inhibitors, and lysosomotropic agents. Mol. Pharmacol. 65, 181-195. doi: 10.1124/mol.65.1.181.
28. Link, G., Tirosh, R., Pinson, A., and Hershko, C. (1996). Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction. J. Lab. Clin. Med. 127, 272-278. doi: 10.1016/S0022-2143(96)90095-5.
29. Lipshultz, S. E., Cochran, T. R., Franco, V. I., and Miller, T. L. (2013a). Treatment-related cardiotoxicity in survivors of childhood cancer. Nat. Rev. Clin. Oncol. 10, 697-710. doi: 10.1038/nrclinonc.2013.195.
30. Lipshultz, S. E., Lipsitz, S. R., Kutok, J. L., Miller, T. L., Colan, S. D., Neuberg, D. S., et al. (2013b). Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. Cancer 119, 3555-3562. doi: 10.1002/cncr.28256.
31. Menna, P., Salvatorelli, E., and Minotti, G. (2010). Anthracycline degradation in cardiomyocytes: a journey to oxidative survival. Chem. Res. Toxicol. 23, 6-10. doi: 10.1021/tx9003424.
32. Minotti, G., Cairo, G., and Monti, E. (1999). Role of iron in anthracycline cardiotoxicity: new tunes for an old song? FASEB J. 13, 199-212.
33. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., and Gianni, L. (2004a). Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56, 185-229. doi: 10.1124/pr.56.2.6.
34. Minotti, G., Recalcati, S., Menna, P., Salvatorelli, E., Corna, G., and Cairo, G. (2004b). Doxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanisms. Methods Enzymol. 378, 340-361. doi: 10.1016/S0076-6879(04)78025-8.
35. Minotti, G., Recalcati, S., Mordente, A., Liberi, G., Calafiore, A. M., Mancuso, C., et al. (1998). The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human myocardium. FASEB J. 12, 541-552.
36. Minotti, G., Ronchi, R., Salvatorelli, E., Menna, P., and Cairo, G. (2001). Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res. 61, 8422-8428.
37. Miranda, C. J., Makui, H., Soares, R. J., Bilodeau, M., Mui, J., Vali, H., et al. (2003). Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin. Blood 102, 2574-2580. doi: 10.1182/blood-2003-03-0869.
38. Muckenthaler, M. U., Galy, B., and Hentze, M. W. (2008). Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. Annu. Rev. Nutr. 28, 197-213. doi: 10.1146/annurev.nutr.28.061807.155521.
39. Octavia, Y., Tocchetti, C. G., Gabrielson, K. L., Janssens, S., Crijns, H. J., and Moens, A. L. (2012). Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J. Mol. Cell Cardiol. 52, 1213-1225. doi: 10.1016/j.yjmcc.2012.03.006.
40. Panjrath, G. S., Patel, V., Valdiviezo, C. I., Narula, N., Narula, J., and Jain, D. (2007). Potentiation of doxorubicin cardiotoxicity by iron loading in a rodent model. J. Am. Coll. Cardiol. 49, 2457-2464. doi: 10.1016/j.jacc.2007.02.060.
41. Recalcati, S., Minotti, G., and Cairo, G. (2010). Iron regulatory proteins: from molecular mechanisms to drug development. Antioxid. Redox. Signal. 13, 1593-1616. doi: 10.1089/ars.2009.2983.
42. Rouault, T. A. (2006). The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat. Chem. Biol. 2, 406-414. doi: 10.1038/nchembio807.
43. Sacco, G., Giampietro, R., Salvatorelli, E., Menna, P., Bertani, N., Graiani, G., et al. (2003). Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity. Br. J. Pharmacol. 139, 641-651. doi: 10.1038/sj.bjp.0705270.
44. Salvatorelli, E., Guarnieri, S., Menna, P., Liberi, G., Calafiore, A. M., Mariggiò, M. A., et al. (2006). Defective one-or two-electron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron addition. J. Biol. Chem. 281, 10990-11001. doi: 10.1074/jbc.M508343200.
45. Simůnek, T., Stérba, M., Popelová, O., Adamcová, M., Hrdina, R., and Gersl, V. (2009). Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol. Rep. 61, 154-171.
46. Spagnuolo, R. D., Recalcati, S., Tacchini, L., and Cairo, G. (2011). Role of hypoxia-inducible factors in the dexrazoxane-mediated protection of cardiomyocytes from doxorubicin-induced toxicity. Br. J. Pharmacol. 163, 299-312. doi: 10.1111/j.1476-5381.2011.01208.x.
47. Stěrba, M., Popelová, O., Vávrová, A., Jirkovský, E., Kovaříková, P., Geršl, V., et al. (2013). Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid. Redox. Signal. 18, 899-929. doi: 10.1089/ars.2012.4795.
48. Thomas, C. E., and Aust, S. D. (1986). Reductive release of iron from ferritin by cation free radicals of paraquat and other bipyridyls. J. Biol. Chem. 261, 13064-13070.
49. Xu, X., Persson, H. L., and Richardson, D. R. (2005). Molecular pharmacology of the interaction of anthracyclines with iron. Mol. Pharmacol. 68, 261-271.
50. Zhang, S., Liu, X., Bawa-Khalfe, T., Lu, L. S., Lyu, Y. L., Liu, L. F., et al. (2012). Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 18, 1639-1642. doi: 10.1038/nm.2919.